28170 Neutralizing interleukin-13 increases skin microbial diversity: Results from a phase 3, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis - 07/08/21
Doi : 10.1016/j.jaad.2021.06.722
Lisa A. Beck, MD
Department of Dermatology, Medicine and Pathology, University of Rochester Medical Center
Andrew Pink, BMedSci (Hons), BMBS, PhD, MRCP
St. John’s Institute of Dermatology, Guy’s and St. Thomas’ Hospitals
Lawrence Eichenfield, MD
Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine
Le texte complet de cet article est disponible en PDF.
| Commercial Disclosure: The tralokinumab ECZTRA 1 study was sponsored by LEO Pharma. Medical writing and editorial support were provided by Jasper Neergaard Jacobsen, PhD, employed by LEO Pharma |
© 2021
Publié par Elsevier Masson SAS.
Vol 85 - N° 3S
P. AB177 - septembre 2021 Retour au numéro
Article précédent
- 28169 Psoriasis in routine clinical care: Complete skin clearance rates with guselkumab increase through week 52—Results from the real-life PERSIST study
- Matthias Hoffmann, Michael Sticherling, Bernhard Korge, Dariusch Mortazawi, Yvonne Personke, Mario Gomez, Sven Wegner, Sascha Gerdes
- 28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
- Andrew Blauvelt, Andreas Wollenberg, Andrew Pink, Ketty Peris, April Armstrong, Lynda Spelman, Hidehisa Saeki, Charles Lynde, Pedro Herranz, Sebastien Barbarot, Eric Simpson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?